Human Genome Sciences appoints Allan Baxter to board of directors
This article was originally published in Scrip
Executive Summary
Human Genome Sciences has appointed Allan Baxter, previously senior vice-president of medicines development at GlaxoSmithKline (GSK), to its board of directors. Mr Baxter had a 30 year career at GSK, and created and led six of its centres of excellence for drug discovery, later taking on worldwide responsibility for its late-stage portfolio of investigational medicines from Phase II through to lifecycle management.